News | Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial from Foundation Fighting Blindness

Foundation Fighting Blindness

News | Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial

3 minutes Posted Oct 3, 2022 at 7:34 pm.

0:00

3:24

Share at current time

Show notes

The company is planning to move the emerging treatment into a pivotal trial